Royalty Pharma plc splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Financial Royalty Assets at $647.6 million, 94% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2,617
|
690
|
674
|
631
|
622
|
609
|
579
|
568
|
594
|
| Financial Royalty Assets |
2,473
+10.9%
share 94.5%
|
648
+11.9%
share 93.8%
|
638
+15.9%
share 94.6%
|
595
+10.3%
share 94.4%
|
592
+5.4%
share 95.2%
|
579
share 95.0%
|
550
share 95.1%
|
539
share 94.9%
|
562
share 94.6%
|
| Royalty Income Other |
144
+20.5%
share 5.5%
|
42
+39.4%
share 6.2%
|
36
+27.9%
share 5.4%
|
36
+23.7%
share 5.6%
|
30
-7.0%
share 4.8%
|
30
share 5.0%
|
28
share 4.9%
|
29
share 5.1%
|
32
share 5.4%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RPRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1802768
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.